Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 7, Pages e1440168
Publisher
Informa UK Limited
Online
2018-02-14
DOI
10.1080/2162402x.2018.1440168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Emphasis on Repair, Not Just Avoidance of Injury, Facilitates Prudent Stereotactic Ablative Radiotherapy
- (2017) D.W. Nathan Kim et al. SEMINARS IN RADIATION ONCOLOGY
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
- (2016) Kristian M. Koller et al. CANCER BIOLOGY & THERAPY
- Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
- (2016) Dan Ishihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
- (2016) Chad Tang et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab
- (2016) Rosie Qin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma
- (2016) Susan M. Hiniker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer
- (2016) Matthew J. Boyer et al. LUNG CANCER
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
- (2016) Saby George et al. JAMA Oncology
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
- (2015) K. A. Ahmed et al. ANNALS OF ONCOLOGY
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- (2015) A. Filatenkov et al. CLINICAL CANCER RESEARCH
- Organ-specific differences in achieving tolerance
- (2015) Maria Lucia L. Madariaga et al. Current Opinion in Organ Transplantation
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
- (2015) J Gao et al. ONCOGENE
- Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
- (2015) Marka Crittenden et al. SEMINARS IN RADIATION ONCOLOGY
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- (2015) S. S. Park et al. Cancer Immunology Research
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy
- (2014) Max M. Wattenberg et al. RADIATION RESEARCH
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- Maximizing Tumor Immunity With Fractionated Radiation
- (2011) Dörthe Schaue et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
- (2009) Y. Lee et al. BLOOD
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Universal Survival Curve and Single Fraction Equivalent Dose: Useful Tools in Understanding Potency of Ablative Radiotherapy
- (2008) Clint Park et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started